Aethlon Medical (NASDAQ:AEMD) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of Aethlon Medical (NASDAQ:AEMD) in a research note issued on Monday. The firm set a “sell” rating on the medical equipment provider’s stock.

Separately, HC Wainwright restated a “buy” rating and set a $7.00 target price on shares of Aethlon Medical in a research note on Friday, November 15th.

Aethlon Medical Price Performance

NASDAQ:AEMD opened at $0.39 on Monday. The business’s 50-day moving average is $0.40 and its two-hundred day moving average is $0.42. Aethlon Medical has a 12 month low of $0.24 and a 12 month high of $2.35. The firm has a market capitalization of $5.48 million, a PE ratio of -0.14 and a beta of 1.79.

Aethlon Medical Company Profile

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.